Fluconazole for the management of invasive candidiasis: Where do we stand after 15 years?

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 3, 2006, Pages 384-410

  Charlier, C ^a,b   Hart, E ^c   Lefort, A ^a   Ribaud, P ^d   Dromer, F ^b   Denning, D W ^e   Lortholary, Oliver ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bone marrow transplantation; Candida spp.; Intensive care unit; Neutropenia; Solid organ transplantation; Systemic candidiasis

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; ANTICONVULSIVE AGENT; ANTILEUKEMIC AGENT; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; LOSARTAN; METHADONE; MICAFUNGIN; MIDAZOLAM; NYSTATIN; PHENYTOIN; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; TACROLIMUS; TERFENADINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; BONE MARROW TRANSPLANTATION; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CHILD CARE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SALIVA LEVEL; DRUG TOLERABILITY; DRUG TOLERANCE; ENDOCARDITIS; ENDOPHTHALMITIS; ENZYME DEFECT; FETOTOXICITY; FUNGAL STRAIN; FUNGEMIA; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HAIR LOSS; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INFECTION PREVENTION; INTENSIVE CARE UNIT; LEUKEMIA; LYMPHOCYTOPENIA; MENINGITIS; MOULD; MUCOSA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEWBORN INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OSTEOARTHRITIS; PATIENT CARE; PATIENT SELECTION; PERITONITIS; PREDICTION; QT PROLONGATION; RECURRENT INFECTION; REVIEW; SKIN MANIFESTATION; SPECIES IDENTIFICATION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; THRUSH; TOXIC HEPATITIS; YEAST;

ANTIFUNGAL AGENTS; CANDIDIASIS; FLUCONAZOLE; HUMANS; TIME FACTORS;

EID: 32644433583     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki473     Document Type: Review

References (228)

1. Richardson K. The discovery and profile of fluconazole. J Chemother 1990; 2: 51-4.
2. Richardson K, Brammer KW, Marriott MS et al. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 1985; 27: 832-5.
3. Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seatedfungal infections. J Antimicrob Chemother 1988; 21: 665-72.
4. Van't Wout JW, de Graeff-Meeder ER, Paul LC et al. Treatment of two cases of cryptococcal meningitis with fluconazole. Scand J Infect Dis 1988; 20: 193-8.
5. Tucker RM, Williams PL, Arathoon EG et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 1988; 32: 369-73.
6. Byrne WR, Wajszczuk CP. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): Successful treatment with fluconazole after failure of amphotericin B. Ann Intern Med 1988; 108: 384-5.
7. Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother 1987; 19: 171-4.
8. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997; 33: 52-77.
9. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994; 13: 325-9.
10. Schwarze R, Penk A, Pittrow L. Administration of fluconazole in children below 1 year of age. Mycoses 1999; 42: 3-16.
11. Schwarze R, Penk A, Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res 2000; 5: 203-8.
12. Thaler F, Bernard B, Tod M et al. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother 1995; 5: 1154-6.
13. Bozzette SA, Gordon RL, Yen A et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: Case report. Clin Infect Dis 1992; 4: 701-3.
14. Debruyne D, Ryckelynck JP, Moulin M et al. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1990; 18: 491-8.
15. Tod M, Lortholary O, Padoin C et al. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3: 143-4.
16. Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994; 3: 147-56.
17. Fasano C, O'Keefe J, Gibbs D. Fluconazole treatment of children with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994; 13: 344-7.
18. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: Report of an additional patient. Am J Med Genet 1997; 72: 253-6.
19. Buijk SL, Gyssens IC, Mouton JW et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 2001; 27: 115-21.
20. El-Yazigi A, Ellis M, ErnstPet al. Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients. Antimicrob Agents Chemother 1997; 41: 914-17.
21. Finch CK, Green CA, Self TH. Fluconazole-carbamazepine interaction. South Med J 2002; 95: 1099-100.
22. Tucker RM, Denning DW, Hanson RH et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: In vitro and clinical observations. Clin Infect Dis 1992; 14: 165-74.
23. Stockley IH. Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management, 6th edn. London, UK: Pharmaceutical Press, 2002.
24. von Moltke LL, Greenblatt DJ, Duan SX et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996; 16: 104-12.
25. Brockmeyer NH, Tillmann I, Mertins L et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997; 2: 377-83.
26. van Burik JA, Leisenring W, Myerson D et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine 1998; 77: 246-54.
27. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002; 34: 1386-90.
28. Garbino J, Lew DP, Romand JA et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-17.
29. Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994; 28: 1177-81.
30. Crerar-Gilbert A, Boots R, Fraenkel D et al. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care 1999; 27: 650-2.
31. Pappas PG, Kauffman CA, Perfect J et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995; 123: 354-7.
32. Stevens DA, Diaz M, Negroni R et al. Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group. Chemotherapy 1997; 5: 371-7.
33. Anaissie EJ, Kontoyiannis DP, Huls C et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: 599-602.
34. Gussenhoven MJ, Haak A, Peereboom-Wynia JD et al. Stevens-Johnson syndrome after fluconazole. Lancet 1991; 338: 120.
35. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43: 1955-60.
36. Koks CH, Crommentuyn KM, Hoetelmans RM et al. Can fluconazole concentrations in saliva be used for therapeutic drug monitoring? Ther Drug Monit 2001; 4: 449-53.
37. Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-9.
38. Pittrow L, Penk A. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints. Mycoses 1997; 40: 25-32.
39. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptualframeworkand analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
40. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. International Fungal Surveillance Participant Group. Clin Microbiol Infect 2004; 10 Suppl 1: 11-23.
41. Tortorano AM, Rigoni AL, Biraghi E et al. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: Antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-82.
42. Pfaller MA, Messer SA, Boyken L et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: A global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-6.
43. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-88.
44. Singh N, Wagener MM, Marino IR et al. Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices. Transplantation 2002; 73: 63-7.
45. Fung JJ. Fungal infection in liver transplantation. Transplant Infect Dis 2002; 4: 18-23.
46. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-37.
47. Gladdy RA, Richardson SE, Davies HD et al. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 1999; 5: 16-24.
48. Castaldo P, Stratta RJ, Wood RP et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149-56.
49. Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023-9.
50. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-13.
51. Dockrell DH, Mendez JC, Jones M et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999; 67: 399-403.
52. Tollemar J, Ericzon BG, Barkholt L et al. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc 1990; 22: 1826-7.
53. Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583-8.
54. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74: 688-95.
55. Tortorano AM, Viviani MA, Pagano A et al. Candida colonization in orthotopic liver tranplantation: Fuconazole versus oral amphoericin B. J Mycol Med 1995; 5: 21-4.
56. Kung N, Fisher N, Gunson B et al. Fluconazole prophylaxis for high-risk liver transplant recipients. Lancet 1995; 345: 1234-5.
57. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
58. Paya CV. Prevention of fungal infection in transplantation. Transpl Infect Dis 2002; 4: S46-51.
59. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10: 477-504.
60. Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg 1996; 183: 307-16.
61. Lumbreras C, Fernandez I, Velosa J et al. Infectious complications following pancreatic transplantation: Incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995; 20: 514-20.
62. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1: 229-36.
63. Kusne S, Furukawa H, Abu-Elmagd K et al. Infectious complications after small bowel transplantation in adults: An update. Transplant Proc 1996; 28: 2761-2.
64. Paterson DL, Ndirangu M, Kwak EJ et al. Opportunistic infections in solid-organ transplant recipients pre-treated with alumetuzumab. In: Abstracts of the Forty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract K-1427, p. 357. American Society for Microbiology, Washington, DC, USA.
65. Kramer MR, Marshall SE, Starnes VA et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993; 153: 2010-6.
66. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
67. Dykewicz CA, Centers for Disease Control and Prevention (U.S.); Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-44.
68. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994; 18: 273-81.
69. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
70. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
71. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
72. Alangaden G, Chandrasekar PH, Bailey E et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 14: 919-24.
73. Wolff SN, Fay J, Stevens D et al. Fluconazole versus low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25: 853-9.
74. Annaloro C, Oriana A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995; 80: 512-17.
75. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
76. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections inpatients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
77. MacMillan ML, Goodman JL, DeFor TE et al. Fluconazole to prevent yeast infections in bone marrow transplantation patients: A randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112: 369-79.
78. Marr KA, Seidel K, White TC et al. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
79. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
80. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-84.
81. Laverdiere M, Rotstein C, Bow EJ et al. Impact of fluconazole prophylaxis on fungal colonizatin and infection rates in neutropenic patients. The Canadian Fluconazole Study. J. Animicrob Chemother 2000; 46: 1001-8.
82. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495-503.
83. Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy 1994; 40: 136-43.
84. Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40.
85. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1997; 71: 284-6.
86. Kern W, Behre G, Rudolf T et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: Results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998; 83: 291-301.
87. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use,and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-41.
88. Egger T, Gratwohl A, Tichelli A et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 1995; 3: 139-46.
89. Morgenstern GR, Prentice AG, Prentice H et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-11.
90. Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3-11.
91. Philpott-Howard JN, Wade JJ, Mufti GJ et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 1993; 31: 973-84.
92. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994; 13: 330-7.
93. Menichetti F, Del Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994; 120: 913-18.
94. Akiyama H, Mori S, Tanikawa S et al. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1996; 36: 373-8.
95. Meunier F, Aoun M, Janssens M et al. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole versus oral amphotericin B. Drug Invest 1991; 3: 258-65.
96. Rozenberg-Arska M, Dekker AW, Branger J et al. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 1991; 27: 369-76.
97. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematol Blood Transfus 1990; 33: 546-50.
98. Bodey GP, Anaissie EJ, Elting LS et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73: 2099-106.
99. Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-25.
100. Bow EJ, Laverdiere M, Lussier N et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
101. Viscoli C, Paesmans M, Sanz M et al. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis 2001; 32: 1532-7.
102. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
103. Cornely OA, Bohme A, Buchheidt D et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2: 186-200.
104. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
105. Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18-24.
106. Marchetti O, Bille J, Fluckiger U et al. Fungal Infection Network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: Secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
107. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
108. Ibanez-Nolla J, Nolla-Salas M, Leon MA et al. Early diagnosis of candidiasis in nonneutropenic critically ill patients. J Infect 2004; 48: 181-92.
109. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86.
110. Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
111. Sendid B, Poirot JL, Tabouret M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51: 433-42.
112. Bar W, Hecker H. Diagnosis of systemic Candida infections in patients of the intensive care unit. Significance of serum antigens and antibodies. Mycoses 2002; 45: 22-8.
113. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004; 39: S185-92.
114. Sypula WT, Kale-Pradhan PB. Therapeutic dilemma of fluconazole prophylaxis in intensive care. Ann Pharmacother 2002; 36: 155-9.
115. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-8.
116. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1997; 27: 1066-72.
117. Swoboda SM, Merz WG, Lipsetta PA. Candidemia: The impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect 2003; 4: 345-54.
118. Todd JC, O'Neal VG, Grady KP et al. Reduction of secondary mycotic infections in the trauma intensivie care unit with fluconazole. J Trauma 1991; 31: 1722-27.
119. Jacobs S, Price Evans DA, Tariq M et al. Fluconazole improves survival in septic shock: A randomized double-blind prospective study. Crit Care Med 2003; 31: 1938-46.
120. Zervos EE, Fink GW, Norman JG et al. Fluconazole increases bactericidal activity of neutrophils through non-cytokine-mediated pathway. J Trauma 1996; 41: 465-70.
121. Ables AZ, Blumer NA, Valainis GT et al. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: A prospective, double-blind, randomised placebo-controlled trial. Infect Dis Clin Pract 2000; 9: 169-75.
122. Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm 2002; 59: 33-41.
123. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: Analysis of bacterial and fungal resistance. Arch Surg 2000; 135: 160-5.
124. Tortorano AM, Caspani L, Rigoni AL et al. Candidosis in the intensive care unit: A 20-year survey. J Hosp Infect 2004; 57: 8-13.
125. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-85.
126. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically illnon-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
127. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291-4.
128. Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700-5.
129. Leen CL, Dunbar EM, Ellis ME et al. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: A double-blind placebo-controlled study. J Infect 1990; 21: 55-60.
130. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, doubleblind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991; 151: 2458-64.
131. Just-Nubling G, Gentschew G, Meissner K. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991; 10: 917-21.
132. Marriott DJ, Jones PD, Hoy JF et al. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 1993; 158: 312-16.
133. Schuman P, Capps L, Peng G et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126: 689-96.
134. Havlir DV, Dube MP, McCutchan JA et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27: 1369-75.
135. Pagani JL, Chave JP, Casjka C et al. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: A randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 2002; 50: 231-40.
136. Vazquez JA, Peng G, Sobel JD et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001; 33: 1069-75.
137. Delfraissy JF. Prise en charge thérapeutique des patients infectés pas le VIH. Rapport Delfraissy. Paris: Flammarion, 2004.
138. DePauw BE, Raemaekers JM, Donnelly JP et al. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 1995; 70: 83-7.
139. Anaissie EJ, Vartivarian SE, Abi-Said D et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996; 101: 170-6.
140. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
141. Myoken Y, Kyo T, Kohara T et al. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia. Clin Infect Dis 2003; 36: 1496-7.
142. Anttila VJ, Farkkila M, Jansson SE et al. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis. Eur J Clin Microbiol Infect Dis 1997; 16: 637-43.
143. Anaissie E, Bodey GP, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91: 142-50.
144. Kauffman CA, Bradley SF, Ross SC et al. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91: 137-41.
145. Kontoyiannis DP, Luna MA, Samuels BI et al. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14: 721-39.
146. Graninger W, Presteril E, Schneeweiss B et al. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993; 26: 133-46.
147. Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 337-45.
148. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
149. Abele-Horn M, Kopp A, Sternberg U et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24: 426-32.
150. Nguyen MH, Peacock JE Jr, Tanner DC et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-35.
151. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
152. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
153. Sugar AM, Saunders C, Diamond RD et al. Successful treatment of Candida osteomyelitis with fluconazole. A noncomparative study of two patients. Diagn Microbiol Infect Dis 1990; 13: 517-20.
154. Tang C. Successful treatment of Candida albicans osteomyelitis with fluconazole. J Infect 1993; 26: 89-92.
155. Lafont A, Olive A, Gelman M et al. Candida albicans spondylodiscitis and vertebral osteomyelitis in patients with intravenous heroin drug addiction. Report of 3 new cases. J Rheumatol 1994; 21: 953-6.
156. Hennequin C, Bouree P, Hiesse C et al. Spondylodiskitis due to Candida albicans: Report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis 1996; 23: 176-8.
157. Jonnalagadda S, Veerabagu MP, Rakela J et al. Candida albicans osteomyelitis in a liver transplant recipient: A case report and review of the literature. Transplantation 1996; 62: 1182-4.
158. Rossel P, Schonheyder HC, Nielsen H. Fluconazole therapy in Candida albicans spondylodiscitis. Scand J Infect Dis 1998; 30: 527-30.
159. Turner DL, Johnson SA, Rule SA. Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B. J Infect 1999; 38: 51-3.
160. El-Zaatari MM, Hulten K, Fares Y et al. Successful treatment of Candida albicans osteomyelitis of the spine with fluconazole and surgical debridement: Case report. J Chemother 2002; 14: 627-30.
161. Seravalli L, Van Linthoudt D, Bernet C et al. Candida glabrata spinal osteomyelitis involving two contiguous lumbar vertebrae: A case report and review of the literature. Diagn Microbiol Infect Dis 2003; 45: 137-41.
162. Garbino J, Schnyder I, LewDP et al. An unusual cause of vertebral osteomyelitis: Candida species. Scand J Infect Dis 2003; 35: 288-91.
163. Tunkel AR,Thomas CY, Wispelwey B. Candidaprosthetic arthritis: Report of a case treated with fluconazole and review of the literature. Am J Med 1993; 94: 100-3.
164. Cushing RD, Fulgenzi WR. Synovial fluid levels of fluconazole in a patient with Candida parapsilosis prosthetic joint infection who had an excellent clinical response. J Arthroplasty 1997; 12: 950.
165. Fukasawa N, Shirakura K. Candida arthritis after total knee arthroplasty - a case of successful treatment without prosthesis removal. Acta Orthop Scand 1997; 68: 306-7.
166. Lerch K, Kalteis T, Schubert T et al. Prosthetic joint infections with osteomyelitis due to Candida albicans. Mycoses 2003; 46: 462-6.
167. Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: An emerging clinical entity. Clin Infect Dis 1997; 25: 608-13.
168. Petrikkos G, Skiada A, Sabatakou H et al. Case report. Successful treatment of two cases of post-surgical sternal osteomyelitis, due to Candida krusei and Candida albicans, respectively, with high doses of triazoles (fluconazole, itraconazole). Mycoses 2001; 44: 422-5.
169. Weers-Pothoff G, Havermans JF, Kamphuis J et al. Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: Case report and review of the literature. Infection 1997; 25: 109-11.
170. Laatikainen L, Tuominen M, von Dickhoff K. Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol 1992; 113: 205-7.
171. Borne MJ, Elliott JH, O'Day DM. Ocular fluconazole treatment of Candida parapsilosis endophthalmitis after failed intravitreal amphotericin B. Arch Ophthalmol 1993; 111: 1326-7.
172. Zarbin MA, Becker E, Witcher J et al. Treatment of presumed fungal endophthalmitis with oral fluconazole. Ophthalmic Surg Lasers 1996; 27: 628-31.
173. Wong VK, Tasman W, EagleRCet al. Bilateral Candida parapsilosis endophthalmitis. Arch Ophthalmol 1997; 115: 670-2.
174. Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: Efficacy of fluconazole therapy. Mycoses 1993; 36: 13-17.
175. del Palacio A, Cuetara MS, Ferro M et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 1993; 36: 193-9.
176. Luttrull JK, Wan WL, Kubak BM et al. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995; 119: 477-81.
177. Akler ME, Vellend H, McNeely DM et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20: 657-64.
178. Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1996; 27: 1012-18.
179. Essman TF, Flynn HW, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28: 185-94.
180. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J et al. Candida albicans endophthalmitis in brown heroin addicts: Response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998; 27: 1130-3.
181. Aleixo MJ, Caldeira L, Ferreira ML. Candida albicans meningitis: clinical case. J Infect 2000 ; 40: 191-2.
182. Inoue Y, Yozu R, Ueda T et al. A case report of Candida parapsilosis endocarditis. J Heart Valve Dis 1998; 7: 240-2.
183. Isalska BJ, Stanbridge TN. Fluconazole in the treatment of candidal prosthetic valve endocarditis. BMJ 1988; 297: 178-9.
184. Martino P, Meloni G, Cassone A. Candidal endocarditis and treatment with fluconazole and granulocyte-macrophage colony-stimulating factor. Ann Intern Med 1990; 112: 966-7.
185. Roupie E, Darmon JY, Brochard L et al. Fluconazole therapy of candidal native valve endocarditis. Eur J Clin Microbiol Infect Dis 1991; 10: 458-9.
186. Hernandez JA, Gonzalez-Moreno M, Llibre JM et al. Candidal mitral endocarditis and long-term treatment with fluconazole in a patient with human immunodeficiency virus infection. Clin Infect Dis 1992; 15: 1062-3.
187. Venditti M, De Bernardis F, Micozzi A, et al. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis 1992; 14: 422-6.
188. Wallbridge DR, McCartney AC, Richardson MD. Fluconazole in the treatment of Candida prosthetic valve endocarditis. Mycoses1993; 36: 259-61.
189. Otaki M, Kitamura N. Candida prosthetic valve endocarditis. An autopsy review. Int Surg 1993; 78: 252-3.
190. Czwerwiec FS, Bilsker MS, Kamerman ML et al. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med 1993; 94: 545-6.
191. Thakur RK, Skelcy KM, Kahn RN et al. Successful treatment of Candida prosthetic valve endocarditis with a combination of fluconazole and amphotericin B. Crit Care Med 1994; 22: 712-14.
192. Cancelas JA, Lopez J, Cabezudo E et al. Native valve endocarditis due to Candida parapsilosis: A late complication after bone marrow transplantation- related fungemia. Bone Marrow Transplant 1994; 13: 333-4.
193. Zahid MA, Klotz SA, Hinthorn DR. Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis. Chest 1994; 105: 1597-8.
194. Wells CJ, Leech G, Lever AM et al. Treatment of native valve Candida endocarditis with fluconazole. J Infect 1995; 31: 233-5.
195. Gilbert HM, Peters ED, Lang SJ et al. Successful treatment of fungal prosthetic valve endocarditis: Case report and review. Clin Infect Dis 1996; 22: 348-54.
196. Nguyen MH, Nguyen ML, Yu VL et al. Candida prosthetic valve endocarditis: Prospective study of six cases and review of the literature. Clin Infect Dis 1996; 22: 262-7.
197. Lejko-Zupanc T, Kozelj M. A case of recurrent Candida parapsilosis prosthetic valve endocarditis: Cure by medical treatment alone. J Infect 1997; 35: 81-2.
198. Joly V, Belmatoug N, Leperre A et al. Pacemaker endocarditis due to Candida albicans: Case report and review. Clin Infect Dis 1997; 25: 1359-62.
199. Rex JH, Walsh T, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.
200. Baddour LM. Long-term suppressive therapy for Candida parapsilosis-induced prosthetic valve endocarditis. Mayo Clin Proc 1995; 70: 773-5.
201. Melgar GR, Nasser RM, Gordon SM. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine 1997; 76: 94-103.
202. Dupont H, Paugam-Burtz C, Muller-Serieys C et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 2002; 137: 1341-6.
203. Lee SC, Fung CP, Chen HY et al. Candida peritonitis due to peptic ulcer perforation: Incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis 2002; 44: 23-7.
204. Levine J, Bernard DB, Idelson BA et al. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: Successful treatment with fluconazole, a new orally active antifungal agent. Am J Med 1989; 86: 825-7.
205. Michel C, Courdavault L, al Khayat R et al. Fungal peritonitis in patients on peritoneal dialysis. Am J Nephrol 1994; 14: 113-20.
206. Wang AY, Yu AW, Li PK et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: Analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000; 36: 1183-92.
207. Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis 2003; 36: 14-18.
208. Kauffman CA, Vazquez JA, Sobel JD et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000, 30: 14-18.
209. Sobel JD, Kauffman CA, McKinsey D et al. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 19-24.
210. Lundstrom T, Sobel J. Nosocomial candiduria: A review. Clin Infect Dis 2001; 32: 1602-7.
211. Kaufman D, Boyle R, Hazen KC et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345: 1660-6.
212. Kicklighter SD, Springer SC, Cox T et al. Fluconazole for the prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107: 293-8.
213. McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2004: CD003850.
214. Agarwal J, Bansal S, Malik G K et al. Trends in neonatal septicemia: emergence of non-albicans Candida. Indian Pediatr 2004; 41: 712-15.
215. Fasano C, O'Keefe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994; 13: 351-4.
216. Wainer S, Cooper PA, Gouws H et al. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997; 16: 763-7.
217. Huang YC, Lin TY, Lien RI et al. Fluconazole therapy in neonatal candidemia. Am J Perinatol 2000; 17: 411-15.
218. Huttova M, Hartmanova I, Kralinsky K et al. Candida fungemia in neonates treated with fluconazole: Report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998; 17: 1012-15.
219. Gurpinar AN, Balkan E, Kilic N et al. Fluconazole treatment of neonates and infants with severe fungal infections. J Int Med Res 1997; 25: 214-18.
220. Driessen M, Ellis JB, Muwazi F et al. The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Pediatr 1997; 17: 263-71.
221. Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr Infect Dis J 1997; 15: 1107-12.
222. Marr B, Gross S, Cunningham C et al. Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis 1994; 19: 795-6.
223. Oleinik EM, Della-Latta P, Rinaldi MG et al. Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol 1993; 10: 313-15.
224. Mondal RK, Singhi SC, Chakrabarti A. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: A preliminary study. Pediatr Crit Care Med 2004; 5: 561-5.
225. Viscoli C, Castagnola E, Fioredda F et al. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991; 35: 365-7.
226. Decruyenaere J, Colardyn F, Vogelaers D et al. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplant Proc 1995; 27: 3515-16.
227. Koh LP, Kurup A, Goh YT et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002; 71: 260-7.
228. Gluckman E, Esperou-Bourdeau H, Ribaud P et al. Comparaison entre le fluconazole et le kétoconazole pour la prophylaxie des infections fongiques chez les patients traités par greffe de moelle allogénique. Cah Oncol 1993; 2: 167-9.